Select Bibliography

Filter by any of these (after searching):

Molina, Julian R.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 9 items

A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261

Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010

Manuscript - Primary - Primary - Respiratory - NCCTG-N0326

A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013

Manuscript - Primary - Primary - Respiratory - NCCTG-N0528

NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status

Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014

Manuscript - Primary - Primary - Respiratory - NCCTG-N0821

Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials

Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011

Manuscript - Primary - Primary - Respiratory - NCCTG-N0424

NCCTG Phase II Trial (N0621) of the SRC inhibitor AZD0530 after 4 cycles of cytoreductive chemotherapy for patients with Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Molina, Julian R. , Foster, Nathan R. , Nelson, Garth D. ... - IASLC (WCLC) - J Thorac Oncol - 2009

Abstract - Primary - Primary - Respiratory - NCCTG-N0621

A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Molina, Julian R. , Foster, Nathan R. , Reungwetwattana, Thanyanan ... - - Lung Cancer - 2014

Manuscript - Primary - Primary - Respiratory - NCCTG-N0621

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

Parikh, Kaushal , Mandrekar, Sumithra J. , Allen‐Ziegler, Katie ... - - Oncologist - 2020

Manuscript - Primary - Primary - Respiratory - NCCTG-N0623

A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study

Schenk, Erin L. , Mandrekar, Sumithra J. , Dy, Grace K. ... - - J Thorac Oncol - 2020

Manuscript - Primary - Primary - Respiratory - NCCTG-N0923

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321

Zhao, Yujie , Foster, Nathan R. , Meyers, Jeffrey P. ... - - J Thorac Oncol - 2015

Manuscript - Primary - Primary - Respiratory - NCCTG-N0321